Toshiba debuts new cardiac ultrasound devices; Ad-Tech faces Class I recall over microelectrode fears;

 @FierceMedDev: St. Jude eyes FDA approval with trial for stroke-stopping heart plug. News | Follow @FierceMedDev

 @MarkHFierce: Sequenom's Down Syndrome prenatal Dx juiced revenue tremendously in 2012. Release | Follow @MarkHFierce

 @DamianFierce: Florida's OrbusNeich is suing Boston Scientific, saying the device giant violated its stent patents. Story | Follow @DamianFierce

> Boston Scientific ($BSX) wants patients with S-ICD devices to seek a software update from their doctors to address a potential problem with the implants. Story

> Toshiba used the American College of Cardiology conference in San Francisco to debut two new cardiac ultrasound systems. Release

> AliveCor's mobile heart monitor for the iPhone is now available for prescription--the first FDA-cleared mobile device-based ECG monitor compatible with the iPhone 4 and 4S. Release

> Inrad Optics will be laying off 9% of its workforce. The company makes optical components and crystalline devices, in part, for medical, laboratory and government clients. Release

> Sekisui Diagnostics moved its headquarters from Framingham, MA, to nearby Lexington. The company also has operations in San Diego, CA; Stamford, CT; Exton, PA; England and Germany. Release

> Ad-Tech Medical Instrument Corp. has been slapped with a Class I FDA recall over possibly defective microelectrodes that could cause brain injury. FDA notice

Biotech News

 @FierceBiotech: In case you missed it yesterday: Sirtris co-founder fires back against resveratrol critics. Article | Follow @FierceBiotech

@JohnCFierce: J&J planning 5 new clinical studies for Xarelto, including CHF. | Follow @JohnCFierce

@RyanMFierce: Failed ALS study haunts Biogen in lawsuit from unhappy partner. Story | Follow @RyanMFierce

> Scientist spotlights potential Achilles heel of therapeutic cancer vaccines. Report

> Biotech PTC reloads coffers with $60M for late-stage DMD drug. More

Pharma News

@FiercePharma: In case you missed it: More job cuts at Merck as mfring in Rathdrum, Ireland, is phased out. 280 positions to go. Report | Follow @FiercePharma

@EricPFierce: JNJ withdraws 2.3 million packs of K-Y sex lubricants and won't bring them back. FDA says no safety risk. More | Follow @EricPFierce

> Eisai fires back at G-BA rebuff of Fycompa. Story

> Bayer, J&J test Xarelto uses, even as ACS indication eludes. Article

> WHO finds Syrian situation grim, drug shortages critical. Report

Suggested Articles

Synthetic DNA weaver Twist Bioscience announced a handful of new collaborations this week amidst a $140 million raise from an underwritten offering.

The FDA has announced a series of actions aimed at limiting the use of power morcellators in gynecologic surgeries.

J&J launched a virtual clinical study to gauge whether Apple’s iPhone and ECG-enabled smartwatch can help reduce the risk of stroke and catch AFib.